Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein, CF Summary

• Additional Information: His-tag
• Details of Functionality: Measured by its ability to inhibit TNF-beta -mediated cytotoxicity using L‑929 mouse fibroblast cells. The ED₅₀ for this effect is 2.5-10 µg/mL in the presence of 50 pg/mL of Recombinant Human TNF‑ beta /TNFSF1 (Catalog # 211-TB).
• Source: Mouse myeloma cell line, NS0-derived human HVEM/TNFRSF14 protein
  

  Human HVEM Pro37-Val202 (Ser108Thr; Ala140Arg) Accession # Q92956.3	IEGRMD	Human IgG1 (Pro100-Lys330)	6-His tag
  N-terminus			C-terminus

• Accession #: Q92956.3
• N-terminal Sequence: Pro37
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: TNFRSF14
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 45 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein, CF

• ATAR
• CD270 antigen
• CD270
• CD40-like protein
• Herpes virus entry mediator A
• Herpesvirus entry mediator A
• HveA
• HVEM
• HVEMTR2HVEAATAR
• LIGHTR
• TNFRSF14
• tumor necrosis factor receptor superfamily member 14
• tumor necrosis factor receptor superfamily, member 14 (herpesvirus entrymediator)
• Tumor necrosis factor receptor-like 2
• tumor necrosis factor receptor-like gene2

Background

HVEM (herpesvirus entry mediator), also known as TNFRSF14 and CD270, is a type I membrane protein in the TNF receptor superfamily, and it can both promote and inhibit T cell activity (1). Mature human HVEM consists of a 164 amino acid (aa) extracellular domain (ECD) with three cysteine-rich domains (CRD), a 21 aa transmembrane segment, and a 60 aa cytoplasmic tail with a TRAF interaction domain (2, 3). Within the ECD, human HVEM shares 55% aa sequence identity with mouse and rat HVEM. Alternative splicing generates an additional isoform with a substitution of the N-terminal 10 amino acids including the signal peptide. HVEM is highly expressed on naïve CD4⁺ T cells, CD8⁺ T memory cells, regulatory T cells, dendritic cells, monocytes, and neutrophils (4-8). Its expression declines during effector T cell activation but is up-regulated during Treg activation (4, 5). HVEM functions as a receptor for BTLA, CD160, LIGHT/TNFSF14, and Lymphotoxin-alpha (4, 9‑12). Ligation of HVEM by LIGHT triggers T cell, monocyte, and neutrophil activation (8, 10) and contributes to Th1 inflammation and cardiac allograft rejection (13, 14). In contrast, HVEM binding to CD160 or BTLA suppresses T cell and dendritic cell activation (4, 7, 9, 10) and dampens intestinal inflammation (15). HVEM enhances the development of CD8⁺ T cell memory and Treg function (5, 6). It is additionally expressed on intestinal epithelial cells, where its binding by intraepithelial lymphocyte (IEL) expressed CD160 promotes epitheilal integrity and host defense (16). The herpesvirus envelope glycoprotein gD, which binds HVEM to initiate membrane fusion, can antagonize both BTLA and LIGHT binding (2, 9, 11).

1. del Rio, M.L. et al. (2010) J. Leukoc. Biol. 87:223.
2. Montgomery, R.I. et al. (1996) Cell 87:427.
3. Hsu, H. et al. (1997) J. Biol. Chem. 272:13471.
4. Sedy, J. R. et al. (2005) Nat. Immunol. 6:90.
5. Tao, R. et al. (2008) J. Immunol. 180:6649.
6. Steinberg, M.W. et al. (2013) PLoS One 8:e77992.
7. de Trez, C. et al. (2008) J. Immunol. 180:238.
8. Heo, S.K. et al. (2006) J. Leukoc. Biol. 79:330.
9. Gonzalez, L.C. et al. (2005) Proc. Natl. Acad Sci. USA 102:1116.
10. Cai, G. et al. (2008) Nat. Immunol. 9:176.
11. Mauri, D.N. et al. (1998) Immunity 8:21.
12. Harrop, J.A. et al. (1998) J. Biol. Chem. 273:27548.
13. Wang, J. et al. (2005) J. Immunol. 174:8173.
14. Ye, Q. et al. (2002) J. Exp. Med. 195:795.
15. Steinberg, M.W. et al. (2008) J. Exp. Med. 205:1463.
16. Shui, J.W. et al. (2012) Nature 488:222.

Publications for HVEM/TNFRSF14 (356-HV/CF)(3)

Publications using 356-HV/CF

• Boice M, Salloum D, Mourcin F, Sanghvi V, Amin R, Oricchio E, Jiang M, Mottok A, Denis-Lagache N, Ciriello G, Tam W, Teruya-Feldstein J, de Stanchina E, Chan W, Malek S, Ennishi D, Brentjens R, Gascoyne R, Cogne M, Tarte K, Wendel H Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell, 2016-09-29;167(2):405-418.e13. 2016-09-29 [PMID: 27693350] (Bioassay, Human)
• El-Far , Mohamed, Pellerin , Charles, Pilote , Louise, Fortin , Jean-Fra, Lessard , Ivan A D, Peretz , Yoav, Wardrop , Elizabet, Salois , Patrick, Bethell , Richard, Cordingley , Michael, Kukolj , George CD160 isoforms and regulation of CD4 and CD8 T-cell responses. J Transl Med, 2014-09-02;12(0):217. 2014-09-02 [PMID: 25179432] (Bioassay, Human)
• Morishige T, Yoshioka Y, Inakura H, Tanabe A, Yao X, Tsunoda S, Tsutsumi Y, Mukai Y, Okada N, Nakagawa S Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy. Biomaterials, 2010-02-01;31(12):3357-63. 2010-02-01 [PMID: 20117833] (Surface Plasmon Resonance)

Bioinformatics

• Gene Symbol: TNFRSF14
• Uniprot:
  • Q92956.3()